Gene Therapy For Parkinson’s Disease Market Report 2026

Gene Therapy For Parkinson’s Disease Market Overview

• Gene Therapy For Parkinson’s Disease market size has reached to $0.64 billion in 2025 • Expected to grow to $2.05 billion in 2030 at a compound annual growth rate (CAGR) of 26% • Growth Driver: Growing Interest In Personalized Medicine Driving The Growth Of The Market Due To Rising Demand For Targeted And Effective Treatments • Market Trend: Accelerating Development Of Innovative Gene Therapies • North America was the largest region in 2025.

What Is Covered Under Gene Therapy For Parkinson’s Disease Market?

Gene therapy for Parkinson’s disease refers to the use of genetic techniques to introduce, repair, or regulate genes within brain cells. It is designed to restore dopamine production, protect nerve cells, or correct disease-related mutations. The approach aims to slow disease progression and provide sustained symptom relief. The main therapy types of gene therapy for parkinson’s disease are in vivo gene therapy and ex vivo gene therapy. In vivo gene therapy refers to the direct delivery of genetic material into the patient’s body, typically using viral or non-viral vectors, to restore or enhance the function of specific genes involved in Parkinson’s disease progression. These therapies target genes such as aromatic L-amino acid decarboxylase (AADC), glial cell line-derived neurotrophic factor (GDNF), neurturin, and other related genes, and are administered through delivery methods including intracerebral, intravenous, and other approaches. The key end-users include hospitals, specialty clinics, research institutes, and others.

What Is The Gene Therapy For Parkinson’s Disease Market Growth Forecast?

The gene therapy for parkinson’s disease market size is expected to see exponential growth in the next few years. It will grow to $2.05 billion in 2030 at a compound annual growth rate (CAGR) of 26.0%. The growth in the forecast period can be attributed to increasing investments in neurodegenerative disease therapies, rising adoption of personalized gene therapy approaches, expansion of late-stage clinical pipelines, growing demand for disease-modifying treatments, advancement of minimally invasive delivery techniques. Major trends in the forecast period include increasing development of viral vector-based therapies, rising focus on dopamine restoration approaches, growing use of neurotrophic factor gene delivery, expansion of precision intracerebral delivery methods, enhanced emphasis on long-term therapeutic efficacy.

Global Gene Therapy For Parkinson’s Disease Market Segmentation

1) By Therapy Type: In Vivo Gene Therapy, Ex Vivo Gene Therapy 2) By Vector Type: Viral Vectors, Non-Viral Vectors 3) By Target Gene: Aromatic L-Amino Acid Decarboxylase (AADC), Glial Cell Line-Derived Neurotrophic Factor (GDNF), Neurturin, Other Target Genes 4) By Delivery Method: Intracerebral, Intravenous, Other Delivery Methods 5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users Subsegments: 1) By In Vivo Gene Therapy: Viral Vectors, Non-Viral Vectors 2) By Ex Vivo Gene Therapy: Autologous Cell-Based Gene Therapy, Allogeneic Cell-Based Gene Therapy

What Is The Driver Of The Gene Therapy For Parkinson’s Disease Market?

The growing interest in personalized medicine is expected to propel the growth of the gene therapy for Parkinson’s disease market going forward. Personalized medicine refers to a medical approach that tailors treatment and prevention strategies to an individual's genetic makeup, lifestyle, and environment. Interest in personalized medicine is rising due to the growing demand for targeted therapies that improve treatment effectiveness while minimizing adverse side effects. Gene therapy for Parkinson’s disease in personalized medicine is used to deliver tailored genetic modifications that restore dopamine function and address individual patient-specific disease mechanisms. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the US Food and Drug Administration (FDA) granted approval for 16 new personalized treatments for rare disease patients, marking a substantial increase from the 6 approvals in 2022. Therefore, the growing interest in personalized medicine is driving the growth of gene therapy for Parkinson’s disease industry.

Key Players In The Global Gene Therapy For Parkinson’s Disease Market

Major companies operating in the gene therapy for parkinson’s disease market are Merck & Co. Inc., Bayer AG, Sanofi S.A., Eli Lilly and Company, Biogen Inc., PTC Therapeutics Inc., Zambon S.p.A., Oxford BioMedica plc, Voyager Therapeutics Inc., Insilico Medicine Inc., Spur Therapeutics Inc., Cerevance Inc., MeiraGTx Holdings plc, BlackfinBio Inc., Partner Therapeutics Inc., Kenai Therapeutics Inc., CureSen Therapeutics Inc., BioVie Inc., Clexio Biosciences Ltd., Tetraneuron S.L.

Global Gene Therapy For Parkinson’s Disease Market Trends and Insights

Major companies are operating in the gene therapy for Parkinson’s disease market, focusing on developing more precise therapy, such as regenerative medicine advanced therapy, to enhance neuronal survival, restore dopamine function, and provide long-lasting disease-modifying benefits for patients with Parkinson’s disease. Regenerative medicine advanced therapy (RMAT) refers to a special United States Food and Drug Administration (FDA) designation granted to regenerative medicine products, such as cell therapies, gene therapies, and tissue-engineered products, that are intended to treat, modify, reverse, or cure serious or life-threatening diseases. For instance, in February 2025, Asklepios BioPharmaceutical, Inc. (AskBio), a US-based gene therapy company, introduced AB-1005, an investigational AAV2-GDNF gene therapy that received FDA regenerative medicine advanced therapy (RMAT) designation. The designation, which is intended to expedite the development and review of promising therapies, was granted based on data submitted by AskBio, including clinical evidence from its Phase Ib open-label, uncontrolled trial, demonstrating AB-1005’s potential to slow disease progression and improve motor function in Parkinson’s patients.

What Are Latest Mergers And Acquisitions In The Gene Therapy For Parkinson’s Disease Market?

In January 2025, BlackfinBio Limited, a UK-based provider of clinical-stage gene therapy solutions for rare neurological and dopamine-deficiency disorders, acquired the Parkinson’s patent portfolio from Oxford Biomedica plc for an undisclosed amount. Through this acquisition, BlackfinBio aims to advance its BFB-201 program targeting Parkinson’s disease and leverage Oxford Biomedica’s expertise in gene and cell therapy IP to accelerate therapeutic development. Oxford Biomedica plc is a UK-based provider of gene and cell therapy development and vector technologies, bringing valuable intellectual property that complements.

Regional Insights

North America was the largest region in the gene therapy for parkinson’s disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy for parkinson’s disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gene therapy for parkinson’s disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Gene Therapy For Parkinson’s Disease Market?

The gene therapy for parkinson’s disease market consists of revenues earned by entities by providing services such as genetic counseling, preclinical studies, clinical trial management, and personalized treatment planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The gene therapy for parkinson’s disease market also includes sales of viral vectors, aromatic L-amino acid decarboxylase (AADC) gene therapy, glutamic acid decarboxylase (GAD) gene therapy, glial cell line-derived neurotrophic factor (GDNF) or neurturin-based neurotrophic therapies, and glucocerebrosidase (GBA)-targeted gene therapies. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Gene Therapy For Parkinson’s Disease Market Report 2026?

The gene therapy for parkinson’s disease market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the gene therapy for parkinson’s disease industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.